Skip to main content

Advertisement

Log in

The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2–4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

ACT:

Adoptive cell therapy

ALL:

Acute lymphoblastic leukemia

AML:

Acute myeloid leukemia

APC:

Antigen-presenting cell

ATAP:

Advanced Therapy Access Program

CAM-IR:

Cell adhesion-mediated immune resistance

CLR:

C-type lectin receptor

CR:

Complete response

CRC:

Colorectal cancer

CRPC:

Castration resistant prostate cancer

CT:

Cancer testis

Cy:

Cyclophosphamide

DC:

Dendritic cell

GAPVAC:

Glioma Actively Personalized Vaccine Consortium

HGSC:

High grade serous carcinoma

IFA:

Incomplete Freund’s adjuvant

IVAC:

Individualized vaccines for cancer

KNAW:

Royal Netherlands Academy of Arts and Sciences

mDC:

Myeloid DC

MDSC:

Myeloid-derived suppressor cell

MM:

Multiple myeloma

MoDC:

Monocyte-derived DC

NGS:

Next-generation sequencing

NLS:

Nuclear localization signal

NSCLC:

Non-small-cell lung cancer

OS:

Overall survival

PDA:

Pancreatic ductal adenocarcinoma

pDC:

Plasmacytoid DC

PFS:

Progression-free survival

PR:

Partial response

RCC:

Renal cell cancer

SLP:

Synthetic long peptide

TIL:

Tumor infiltrating lymphocyte

TRAMP:

Transgenic adenocarcinoma of mouse prostate

TUMAP:

Tumor associated peptide

T-VEC:

Talimogene laherparepvec

VIN:

Vulvar intraepithelial neoplasia

VSME:

Vaccine-site microenvironment

WT-1:

Wilm’s tumor-1

Conflict of interest

The authors have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Saskia J. A. M. Santegoets.

Additional information

Sara M. Melief and Valeria V. Visconti have contributed equally to this work.

This meeting report is a summary of presentations from the Thirteenth International Conference on Progress in Vaccination against Cancer, PIVAC 13, published together with a series of Focussed Research Reviews based on lectures given at the conference.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melief, S.M., Visconti, V.V., Doorduijn, E.M. et al. The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2–4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches. Cancer Immunol Immunother 63, 1105–1112 (2014). https://doi.org/10.1007/s00262-014-1532-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-014-1532-0

Keywords

Navigation